Patanjali, the Ayurveda company founded by Yoga guru Baba Ramdev, on Tuesday, said that the clinical trials that it had conducted for Covid-19 treatment have been registered with Clinical Trials Registry of India.

Acharya Balkrishna, Chairman, tweeted that Patanjali has cleared the communication gap with the government and the standard protocols were fulfilled for the randomised placebo-controlled clinical trials, and has submitted this information to Ayush Ministry. He also said that the current government promotes Ayurveda.

 

The reply came after the Ministry of Ayush earlier said that it is not aware of the facts of the claims and details of the stated scientific study by the company.

“Patanjali Ayurved Ltd has been asked to provide at the earliest details of the name and composition of the medicines being claimed for Covid treatment; site(s)/hospital(s) where the research study was conducted for Covid-19; protocol, sample size, Institutional Ethics Committee clearance, CTRI registration, and results data of the study (ies),” it said.

It had also asked Patanjali to stop advertising or publicising its claims till the issue is duly examined. The Ministry has also requested the concerned State licensing authority of Uttarakhand to provide copies of the licence and product approval details of the Ayurvedic medicines that are being used for the treatment of Covid.

On Tuesday, the company launched Ayurvedic medicines ‘Divya Coronil’ and ‘Divya Swasari Vati’ for Covid-19, claiming that it was a cure. At a press conference, the company shared results of a randomised double-blind clinical trial conducted by Patanjali Research Institute, in collaboration with the National Institute of Medical Sciences (NIMS University), on 100 Covid-19 patients.

“In the group that was given the drugs, 69 per cent tested negative for Covid-19 on the third day. By the seventh day, all patients in the drug arm recovered. There were no deaths observed in the study,” said Ramdev.

Patanjali has yet not published the data from its study in any journal. “The scientific prospects of these Ayurvedic medicines are currently under the peer review process for their publication in esteemed journals of international repute,” the company states.

Published on June 23, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill.

In these difficult times, we, at BusinessLine, are trying our best to ensure the newspaper reaches your hands every day. You can also access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all our readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. You can help us by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section.

Our subscriptions start as low as Rs 199/- per month. A yearly package costs just Rs. 999 – a mere Rs 2.75 per day, less than a third the price of a cup of roadside chai..

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism